Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHT on Liver Function and NAFLD in Postmenopausal Women
NCT07103603Completed
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of semaglutide + estradiol + progesterone in non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis (2 arms). Primary endpoint: Attenuation Imaging value at 6 months. Started Oct 2024; status: completed.
02
Drugs
semaglutide + estradiol + progesterone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)hepatic steatosis
Beyond the preview
Go deeper on NCT07103603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103603.